vs
莱迪思半导体（LSCC）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
莱迪思半导体的季度营收约是VERACYTE, INC.的1.0倍（$145.8M vs $139.1M），VERACYTE, INC.净利率更高（20.6% vs -5.2%，领先25.9%），莱迪思半导体同比增速更快（24.2% vs 21.5%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 1.8%）
莱迪思半导体是美国专注于低功耗现场可编程门阵列（FPGA）设计制造的半导体企业，1983年成立，1989年上市，总部位于俄勒冈州希尔斯伯勒硅林区，在圣何塞、上海、马尼拉、槟城、新加坡等地设有运营网点，截至2022年员工超1000人，年营收超6.6亿美元。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
LSCC vs VCYT — 直观对比
营收规模更大
LSCC
是对方的1.0倍
$139.1M
营收增速更快
LSCC
高出2.7%
21.5%
净利率更高
VCYT
高出25.9%
-5.2%
两年增速更快
VCYT
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $145.8M | $139.1M |
| 净利润 | $-7.6M | $28.7M |
| 毛利率 | 68.5% | 72.7% |
| 营业利润率 | 0.7% | 16.3% |
| 净利率 | -5.2% | 20.6% |
| 营收同比 | 24.2% | 21.5% |
| 净利润同比 | -146.3% | — |
| 每股收益（稀释后） | $-0.06 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSCCVCYT
| Q1 26 | $145.8M | $139.1M | ||
| Q4 25 | — | $140.6M | ||
| Q3 25 | $133.3M | $131.9M | ||
| Q2 25 | $124.0M | $130.2M | ||
| Q1 25 | $120.2M | $114.5M | ||
| Q4 24 | $117.4M | $118.6M | ||
| Q3 24 | $127.1M | $115.9M | ||
| Q2 24 | $124.1M | $114.4M |
净利润LSCCVCYT
| Q1 26 | $-7.6M | $28.7M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | $2.8M | $19.1M | ||
| Q2 25 | $2.9M | $-980.0K | ||
| Q1 25 | $5.0M | $7.0M | ||
| Q4 24 | $16.5M | $5.1M | ||
| Q3 24 | $7.2M | $15.2M | ||
| Q2 24 | $22.6M | $5.7M |
毛利率LSCCVCYT
| Q1 26 | 68.5% | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | 67.9% | 69.2% | ||
| Q2 25 | 68.4% | 69.0% | ||
| Q1 25 | 68.0% | 69.5% | ||
| Q4 24 | 61.1% | 66.4% | ||
| Q3 24 | 69.0% | 68.2% | ||
| Q2 24 | 68.3% | 68.1% |
营业利润率LSCCVCYT
| Q1 26 | 0.7% | 16.3% | ||
| Q4 25 | — | 26.4% | ||
| Q3 25 | -1.2% | 17.4% | ||
| Q2 25 | 3.8% | -4.0% | ||
| Q1 25 | 5.8% | 2.5% | ||
| Q4 24 | -10.4% | 3.5% | ||
| Q3 24 | 5.9% | 10.4% | ||
| Q2 24 | 18.2% | 4.0% |
净利率LSCCVCYT
| Q1 26 | -5.2% | 20.6% | ||
| Q4 25 | — | 29.3% | ||
| Q3 25 | 2.1% | 14.5% | ||
| Q2 25 | 2.3% | -0.8% | ||
| Q1 25 | 4.2% | 6.2% | ||
| Q4 24 | 14.1% | 4.3% | ||
| Q3 24 | 5.7% | 13.1% | ||
| Q2 24 | 18.2% | 5.0% |
每股收益（稀释后）LSCCVCYT
| Q1 26 | $-0.06 | $0.35 | ||
| Q4 25 | — | $0.50 | ||
| Q3 25 | $0.02 | $0.24 | ||
| Q2 25 | $0.02 | $-0.01 | ||
| Q1 25 | $0.04 | $0.09 | ||
| Q4 24 | $0.12 | $0.07 | ||
| Q3 24 | $0.05 | $0.19 | ||
| Q2 24 | $0.16 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.9M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $714.1M | $1.3B |
| 总资产 | $883.1M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LSCCVCYT
| Q1 26 | $133.9M | $439.1M | ||
| Q4 25 | — | $362.6M | ||
| Q3 25 | $117.9M | $315.6M | ||
| Q2 25 | $107.2M | $219.5M | ||
| Q1 25 | $127.6M | $186.1M | ||
| Q4 24 | $136.3M | $239.1M | ||
| Q3 24 | $124.3M | $274.1M | ||
| Q2 24 | $109.2M | $235.9M |
股东权益LSCCVCYT
| Q1 26 | $714.1M | $1.3B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $706.4M | $1.3B | ||
| Q2 25 | $687.0M | $1.2B | ||
| Q1 25 | $707.9M | $1.2B | ||
| Q4 24 | $710.9M | $1.2B | ||
| Q3 24 | $703.5M | $1.2B | ||
| Q2 24 | $698.8M | $1.1B |
总资产LSCCVCYT
| Q1 26 | $883.1M | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | $844.4M | $1.4B | ||
| Q2 25 | $808.6M | $1.3B | ||
| Q1 25 | $823.6M | $1.3B | ||
| Q4 24 | $843.9M | $1.3B | ||
| Q3 24 | $853.7M | $1.3B | ||
| Q2 24 | $827.5M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.6M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $44.0M | — |
| 自由现金流率自由现金流/营收 | 30.2% | — |
| 资本支出强度资本支出/营收 | 9.3% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | $132.6M | — |
8季度趋势，按日历期对齐
经营现金流LSCCVCYT
| Q1 26 | $57.6M | $35.2M | ||
| Q4 25 | — | $52.6M | ||
| Q3 25 | $47.1M | $44.8M | ||
| Q2 25 | $38.5M | $33.6M | ||
| Q1 25 | $31.9M | $5.4M | ||
| Q4 24 | $45.4M | $24.5M | ||
| Q3 24 | $44.0M | $30.0M | ||
| Q2 24 | $21.9M | $29.6M |
自由现金流LSCCVCYT
| Q1 26 | $44.0M | — | ||
| Q4 25 | — | $48.8M | ||
| Q3 25 | $34.0M | $42.0M | ||
| Q2 25 | $31.3M | $32.3M | ||
| Q1 25 | $23.3M | $3.5M | ||
| Q4 24 | $39.7M | $20.4M | ||
| Q3 24 | $39.4M | $27.7M | ||
| Q2 24 | $14.8M | $26.8M |
自由现金流率LSCCVCYT
| Q1 26 | 30.2% | — | ||
| Q4 25 | — | 34.7% | ||
| Q3 25 | 25.5% | 31.8% | ||
| Q2 25 | 25.2% | 24.8% | ||
| Q1 25 | 19.4% | 3.1% | ||
| Q4 24 | 33.8% | 17.2% | ||
| Q3 24 | 31.0% | 23.9% | ||
| Q2 24 | 11.9% | 23.4% |
资本支出强度LSCCVCYT
| Q1 26 | 9.3% | — | ||
| Q4 25 | — | 2.7% | ||
| Q3 25 | 9.8% | 2.1% | ||
| Q2 25 | 5.8% | 1.0% | ||
| Q1 25 | 7.2% | 1.6% | ||
| Q4 24 | 4.9% | 3.5% | ||
| Q3 24 | 3.7% | 1.9% | ||
| Q2 24 | 5.8% | 2.4% |
现金转化率LSCCVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 16.86× | 2.34× | ||
| Q2 25 | 13.23× | — | ||
| Q1 25 | 6.35× | 0.76× | ||
| Q4 24 | 2.75× | 4.80× | ||
| Q3 24 | 6.12× | 1.98× | ||
| Q2 24 | 0.97× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSCC
| Asia | $106.3M | 73% |
| Americas | $21.0M | 14% |
| Europe | $18.5M | 13% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
